Deutsche Bank AG vs Sanofi SA — how do they compare? Deutsche Bank AG trades at $38.4 (market cap $71.96B), while Sanofi SA trades at $43.56 (market cap $104.30B). The key difference: Sanofi SA is the larger of the two by market cap, and Sanofi SA pays the higher dividend (5.55%). Which is the better fit depends on your goals.
| DB | SNY | |
|---|---|---|
Market Cap | $71.96B | $104.30B |
Sector | Financials | Health |
52-Week High | $40.33 | $52.34 |
52-Week Low | $28.37 | $41.33 |
Dividend Yield | 3.04% | 5.55% |
Enterprise Value | — | $124.19B |
Trailing returns across standard periods
Latest headlines on both assets
In July 2019, Deutsche Bank announced another restructuring plan hoping to revitalize revenue, reduce costs, and return to profitability. The largest moving pieces of the new plan is the full exit of global equity sales & trading, the scaling back of its fixed income business, as well as 18,000 FTE reductions until 2022. The remaining core business segments include private banking, corporate banking, asset management, and investment banking.
Read more on DB →Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 10% of total sales, but profits are shared with Regeneron. About 30% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.
Read more on SNY →